Fake Lab Results: How Cannabis Testing Labs Are Lying to Consumers

The cannabis industry runs on a piece of paper. It's called a Certificate of Analysis, or COA, and it's the document a testing lab issues to certify that a batch of cannabis has been tested and meets state safety standards. Pesticides below threshold. Heavy metals below threshold. Microbials below threshold. THC and CBD percentages disclosed.

That paper determines whether the product can legally be sold. It determines what the brand can charge for it. It determines what consumers think they're buying. And in too many cases, it is a lie that the lab knew was a lie when it printed the numbers.

Cannabis lab fraud is not a fringe problem. It has been documented by state regulators in California, Florida, Nevada, Oregon, New York, and other major markets. The mechanisms are predictable, the incentives are obvious, and the consequences for consumers, workers, and patients are real. Here is what's actually going on.

The Business Model That Creates the Fraud

Cannabis testing labs, in every regulated state, operate as private businesses competing for client work. The clients are the brands and cultivators whose products require state-mandated testing. The clients pay the labs. The labs report results.

This is the same structural problem that has plagued every other industry where private parties pay private inspectors to certify their own products. The auditor of a publicly-traded company is paid by the company being audited. The home inspector is paid by the seller, sometimes. Cannabis labs are paid by the brand whose flower they're testing.

When the auditor or inspector or lab issues unfavorable results, the client has a strong incentive to take their business to a different vendor next time. Over enough transactions, this dynamic produces "lab shopping" — brands systematically directing work to whichever lab returns the most favorable numbers.

A lab that consistently reports lower potency, more pesticide hits, or more microbial failures will lose business to labs that report higher potency, fewer pesticides, and fewer fails. Over time, the labs that survive are the labs that meet client expectations. The labs that get pushed out are the labs that adhered to scientific rigor at the cost of repeat business.

That is the engine of cannabis lab fraud. Everything else is mechanism.

The Three Most Common Forms of Fraud

THC potency inflation. This is the most ubiquitous form of cannabis lab fraud, because consumers shop for cannabis primarily on advertised THC percentage. A flower labeled 28% THC sells faster, at a higher price, than the same flower labeled 22% THC, even when blind taste-testing reveals no consistent quality difference. Multiple academic studies and undercover investigations have demonstrated that listed THC percentages on dispensary shelves systematically exceed what the same product tests at when sent to independent third-party labs.

The mechanisms range from outright fabrication (labs reporting numbers that bear no relationship to what they actually measured) to selective sampling (labs sampling only the most resin-coated, top-of-the-jar buds rather than representative samples) to methodological manipulation (calibration tweaks that systematically inflate readings).

Pesticide and microbial result suppression. When a lab detects pesticides or molds or yeasts above regulatory thresholds, the brand has a problem — the batch can't be sold. The brand often has the option to retest at the same lab or a different one. A compromised lab can simply re-run the test until they get a favorable result, then issue the COA based on the favorable run while suppressing the unfavorable runs. In documented cases, labs have certified product as passing without performing the tests at all.

Outright certification fraud. The most extreme form, where labs issue COAs for samples they never tested, batches they never received, or product that was tested with the result inverted. The New York OCM's February 2026 finding against Keystone State Testing — that 54 product lots had been falsely reported as Aspergillus-negative when they were not — falls in this category.

What Has Been Documented State by State

California. In 2023, the state Department of Cannabis Control suspended licenses for a major testing lab after audits revealed inflated potency results across thousands of samples. Subsequent investigations identified additional labs with similar issues. The state introduced standardized reference materials and round-robin testing protocols to detect future inflation, but enforcement remains limited.

Florida. State medical cannabis regulators have repeatedly cited testing labs for methodological failures and potency inflation. In one notable case, a testing lab was found to be reporting THC percentages substantially higher than independent re-testing produced. Brand and lab business relationships were a factor in the regulator's findings.

Nevada. Multiple labs have faced disciplinary action over potency inflation and microbial suppression. In 2018 and again in 2021, the state required mandatory re-tests of large product volumes after labs were found to have produced unreliable results.

Oregon. State regulators have suspended labs over methodological failures and have published advisory bulletins about potency inflation across the industry. Independent academic research conducted at Oregon-licensed labs has documented systematic inflation.

New York. The 2026 Keystone State Testing case is the most recent and one of the most documented. The state's investigation determined that the lab had issued unreliable results across 54 product lots involving Aspergillus reporting and one additional lot involving cadmium. The OCM issued precautionary recalls and is pursuing further enforcement.

Massachusetts, Maryland, Pennsylvania. All have had documented testing lab issues, though enforcement has varied.

The pattern is consistent. Where cannabis is legal, testing fraud has emerged. Where regulators have looked closely, they have found it.

The Consumer Cost

Cannabis lab fraud costs consumers in several ways.

You overpay for inflated potency. If you're shopping by THC percentage and the percentages are inflated by 5–10 points, you're paying premium prices for product that would be marked down if labeled honestly. The premium is not large per-purchase but compounds over time, and is being extracted by the brand and lab at the consumer's expense.

You ingest pesticides and contaminants that the lab certified weren't there. This is the more serious harm. When a lab suppresses pesticide detections or fails to run microbial panels, the consumer loses the protection that the testing system was supposed to provide. The recall histories in Colorado, Maine, and other states are partly histories of testing failures — products that should never have been on shelves but were certified as compliant.

You make purchasing decisions on bad information. Patients managing specific conditions need accurate cannabinoid profiles to dose effectively. Recreational consumers who are new to cannabis use COA data to calibrate experiences. When the data is fabricated, the decisions made on it are corrupted.

You support a market that punishes honest operators. The cultivators and brands that submit honest samples to honest labs face the consequences when failed batches force recalls and re-cultivation. Their less scrupulous competitors who shop labs for favorable results pay no equivalent cost. Over time, this asymmetry pushes honest operators out of the market.

Why State Regulators Struggle to Stop It

Stopping cannabis lab fraud requires either (a) breaking the structural incentive that brands pay labs directly, or (b) extensive ongoing audit infrastructure to detect fraud after it occurs. Both are politically and operationally difficult.

Breaking the brand-pays-lab structure would require a single state-administered testing system, a randomized lab-assignment protocol, or a state-funded testing model. Each of these requires legislative action, ongoing budget appropriations, and regulatory capacity that most state cannabis agencies don't have. New York, with the most active enforcement infrastructure of any state, has begun moving in this direction but faces budget and political constraints.

Audit-based detection requires state regulators to maintain reference labs, conduct round-robin testing, perform unannounced inspections, and aggressively prosecute findings. Most state cannabis agencies are understaffed, under-resourced, and politically vulnerable. The brands and labs being audited fund lobbying operations that the regulator's enforcement budget cannot match.

The result is a system where lab fraud is detected episodically, when egregious enough or when independent journalists or academics produce evidence regulators cannot ignore. Between episodes, the structural incentives keep producing more fraud.

What to Look for as a Consumer

Identifying lab-fraud red flags is not always possible — by definition, the COAs are designed to look legitimate. But certain signals increase the odds you're looking at fabricated or inflated data.

THC percentages above 32% on flower. Genuine cannabis flower above 32% THC is exceedingly rare in commercial cultivation. Numbers above 35% are essentially impossible in unmodified flower form. If a dispensary is selling flower labeled 36% THC, the COA is almost certainly inflated.

Lab names you don't recognize and can't verify. Look up the lab name on the state regulator's website. Confirm the lab holds an active license. Check whether the lab has been the subject of any recent enforcement action.

COAs where the test date and the package date are months apart. Cannabis testing should occur close to the time the product is packaged. Long gaps suggest the brand is recycling old test results across multiple production runs.

No pesticide or heavy metal panel data on the COA. Some labs issue COAs that show only cannabinoid potency and visually appear complete but omit safety panel results. A complete COA should show pesticide, heavy metal, microbial, residual solvent (for concentrates), and mycotoxin panels at minimum.

Brands that exclusively use a single lab across all their product lines. Multi-lab usage suggests the brand is using lab capacity strategically. Single-lab usage, especially when paired with consistently high THC numbers, can indicate a captive lab relationship.

Products that smell, taste, or smoke noticeably differently from what the COA suggests. Trust your senses. If a flower labeled 28% THC produces an experience consistent with 18% flower, the label is wrong. Either the cannabinoids degraded between testing and purchase, or the testing was inflated.

The Independent Testing Movement

A small but growing movement of independent testing labs and consumer-facing testing services has emerged to counterweight the dominant lab market. Some operate on a subscription basis, sending consumers anonymized test results on commercial products purchased in their markets. Others publish methodology critiques and reference data.

These operations face the same economic pressures as commercial labs, plus the additional headwind of having no captive client base. The ones that have survived have done so by establishing trusted reputations among informed consumers and patient communities, which translates to subscription revenue and grant funding.

If you care about accuracy, support these operations. Reference their work. Use their data when evaluating products. The broader the independent verification ecosystem, the harder it becomes for fraudulent labs and brands to operate without consequences.

What Has to Change

The fixes for cannabis lab fraud are known and have been documented in multiple regulatory studies. They include:

State-administered random lab assignment, where a brand submitting a sample doesn't know which lab will receive it.

Mandatory blind reference samples sent by regulators to all licensed labs at unannounced intervals, with results publicly compared.

Unified state-administered testing protocols that eliminate methodological discretion at the lab level.

Aggressive financial penalties for labs found to have issued fraudulent COAs, scaled to the volume of affected product and the extent of consumer harm.

Public databases of all testing results, queryable by consumers, allowing direct comparison across labs and brands.

Strict separation of brand ownership and lab ownership, with conflict-of-interest disclosures required.

These reforms are not technically difficult. They are politically difficult, because they require sustained regulator commitment in the face of industry resistance. The states that have moved on them have generally done so only after high-profile scandals.

In the meantime, the responsibility for navigating a fraud-prone testing system falls on consumers — who have to evaluate products on the basis of evidence that is partially or wholly fabricated. The information asymmetry favors the brands and the labs. The cost is paid by everyone else.

Demand better.

---

Cannabis.exposed tracks lab enforcement actions, recall events, and independent testing initiatives. If you have direct knowledge of testing lab fraud, contact our editorial team confidentially.

Internal links:

• Pesticide-Laced Weed: The Recalls, The Brands, The Risk to Your Lungs →
• Why Cannabis Brands Keep Getting Sued for Inflated THC Numbers →
• Every Cannabis Recall in 2025–2026: A Running List →